MetaCap

BrainsWay (BWAY) vs InfuSystems (INFU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InfuSystems (INFU) has outperformed BrainsWay (BWAY) over the past year, gaining 51.7% versus a gain of 13.9%. Over five years, BWAY leads with a +130.7% price change compared with -15.9% for INFU. BrainsWay is the larger company by market cap ($341.3 million vs $287.5 million), about 1.2 times the size.

On valuation, BrainsWay trades at a lower forward P/E (17.0x vs 25.6x for InfuSystems). BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus 4.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BWAY+13.90%INFU+51.69%
+138%+55%-29%
Nov 21, 20251 yearNov 20, 2026
BWAY+113.60%INFU-19.70%
+353%+125%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BWAY versus INFU key metrics
MetricBWAYINFU
Share price$8.48$14.35
Market cap$341.35M$287.48M
1-day change-2.86%+2.06%
YTD return-10.83%+59.98%
1-year return+13.90%+51.69%
5-year return+130.75%-15.93%
P/E ratio (TTM)35.3332.61
Forward P/E16.9625.63
EPS (TTM)$0.24$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.02M$143.44M
Revenue growth (YoY)+29.04%+6.36%
Net income (latest FY)$2.92M$6.63M
Gross margin74.56%55.98%
Operating margin3.39%8.31%
Net margin7.12%4.62%
52-week high$17.40$15.47
52-week low$7.30$7.29
Distance from 52-week high-51.26%-7.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+127.24%+28.92%
Average volume110.35K136.60K
Shares outstanding40.25M20.03M
Employees129461
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INFU has outperformed BWAY by 37.8 percentage points over the past year.
  • BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs +6.36%).

About BrainsWay

BWAY stock →

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 129 employees

About InfuSystems

INFU stock →

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.

Health Care · Medical/Dental Instruments · 461 employees

BWAY vs INFU FAQ

Which is bigger, BrainsWay or InfuSystems?

BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $287.48M for InfuSystems (INFU).

Which stock has performed better over the past year, BWAY or INFU?

INFU returned +51.69% over the past 12 months, compared with +13.90% for BWAY (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BWAY or INFU?

INFU has the lower trailing P/E at 32.6, versus 35.3 for BWAY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are BrainsWay and InfuSystems in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons